Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Prothena to Participate in Upcoming Healthcare Conferences
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Prothena Announces Appointment of Daniel G. Welch as Director & Chair Designate
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
Prothena to Report Third Quarter 2023 Financial Results on November 2
Biotech Firm Prothena Is Said to Prepare for Potential Sale